AI智能总结
CONTENTSIntroductionThe Abu Dhabi LandscapeStrategic Impact GoalsKey Trends Impacting the Global Genomics SpaceCase Study: Singapore’s Centralized AI-Enabled Risk StratificationA 0–100 Story: The Genomics “Art of the Possible”Screening ReimaginedHolistic Benefits Beyond LifespanFuture Proofing Abu Dhabi: The Genome OasisStrategic ObjectivesKey Achievements So FarUnderpinning the Ambition: A Foundational Longevity Operating ModelTier A: Foundational Tech and DataTier B: Research and Clinical IntegrationTier C: Ecosystem EnablersA Progression Toward an Omics-Driven FutureConclusionGlossaryCommon Abbreviations 3558111213141718202225262931343637 © Oliver WymanINTRODUCTIONOver the last decade, the spotlight on longevity — expanding not just lifespan but alsohealthspan — has intensified, fueled by scientific advances and a growing desire for moreproactive, personalized care. This focus on extending the healthy phase of life emphasizesa shift from reactive treatment to proactiveprevention.As genomics-related technologies such as high-throughput sequencing, multi-omicsanalytics, and precision medicine continue to evolve, the resulting breakthroughs revealearlier risk factors and pave the way for increasingly tailored interventions. Interest inlongevity has soared alongside these developments, bringing genomics to the forefront asa vital longevity ‘tool’. Longevity is rapidly emerging as a new field of medicine — one thatpromises a paradigm shift in how healthcare is conceived anddelivered.Abu Dhabi, located in the United Arab Emirates (UAE), is uniquely positioned to capitalizeon the developments in genomics, which are key to longevity. The emirate has a rapidlymaturing healthcare infrastructure, digitally proficient population, and governmentcommitment to public health as a strategic priority. Additionally, The Emirati GenomeProgram serves as a strong foundation, with 800,000 genomessequenced.By examining the emirate‘s initiatives and frameworks, we can gain valuable insights intothe broader implications of genomics on healthcare worldwide. Systematically embeddinggenomics into healthcare can accelerate the transition toward preventive, data-centric, andeconomically sustainable medical care. Through this lens, we will present a phased roadmapthat highlights how genomics and longevity can be navigated, offering lessons that can beapplied in diverse contexts around the globe.This whitepaper aimsto:1.Articulatethe multifaceted benefits of genomics for longevity, encompassing improvedclinical outcomes as well as broader economic and socialadvantages.2.IllustrateAbu Dhabi‘s strategic vision for precision medicine, anchored in its existinginitiatives while addressing gaps — providing lessons that can be appliedglobally.3.Delineatethe technical and organizational frameworks required to translate theseobjectives into verifiableoutcomes.4.Presenta phased roadmap that outlines potential pathways for how pilot successes canevolve into a globally acclaimed genomics and longevity ecosystem — viewed throughthe lens of AbuDhabi. © Oliver WymanLongevityThe term longevity describes theability to live a long life beyondthe species-specific average ageat death. In humans, it focuses onextending the period of life withoutnecessarily detailing the quality ofhealth during the latter years © Oliver WymanTHE ABU DHABI LANDSCAPEAbu Dhabi’s healthcare sector has undergone a transformative evolution, with theintroduction of world-class clinical facilities, a focus on patient-centric solutions, and thedevelopment of advanced digital ecosystems (such as Malaffi, Abu Dhabi’s health exchangeplatform introduced in 2019 that connects public and private healthcare providers).Buoyed by significant governmental investments, clear policy frameworks, and leading-edgedigital infrastructure, Abu Dhabi is in the position to scale its genomic programs in a mannerthat not only enhances clinical outcomes but also fortifies economic resilience, curtailsprotracted healthcare expenditures, and positions itself as a nucleus for future biotechprogress. Additionally, the emirate’s demographic diversity — composed of Emiratis anda substantial expatriate population — creates an optimal environment for studying variedgenetic architectures and validating novel interventions.STRATEGIC IMPACT GOALSBeyond improved patient care, the emirate envisions tangible economic and societal gainsemerging from its genomics-driven initiatives. Recent Department of Health Abu Dhabimodeling projects that, by 2040, genomics could realize:•.US $33 billionin cumulative GDP contribution in the emirate (2024-2040)•Over80 new companiesanchored in genomics and related industries•Approximately290 new biotechstartups•Around22,000 jobs, spanning clinical genomics, artificial intelligence (AI) analytics,biotech research and development, and supportfunctionsIn parallel, the government has identified equally striking health and societalbenefits:•More thanUS $800 millionin productivity gains by